Recently, we developed a novel anti-EGFR mAb (EMab-17, IgG2a, kappa) by immunizing mice with an EGFR-overexpressing glioblastoma cell line, LN229 (LN229/EGFR) [21]. Here, EGFR is linked to glioblastoma.